DDInter16 DDInter1055
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Levofloxacin
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Gatifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) upregulates {v} (Gene) ERAP2
ERAP2 {u} (Gene) is upregulated by {v} (Compound) Levofloxacin
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) Levofloxacin
Acetohexamide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Acetohexamide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Acetohexamide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Acetohexamide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Levofloxacin (Compound)
Acetohexamide may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) upregulates ERAP2 (Gene) and ERAP2 (Gene) is upregulated by Levofloxacin (Compound)
Acetohexamide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levofloxacin (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Levofloxacin (Compound)